QUETIAPINE FUMARATE (quetiapine fumarate) by Gen Pharmaceuticals is unclear. Approved for schizophrenia. First approved in 2012.
Drug data last refreshed 21h ago
unclear. However, the efficacy of quetiapine in these indications could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2A (5HT 2A ) antagonism. The active metabolite, N-desalkyl quetiapine (norquetiapine), has similar activity at D 2 , but greater activity at 5HT 2A…
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
Bioequivalence Study of Quetiapine Fumarate Tablets 300 mg Under Fasting Condition
A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended
Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients
Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients
Worked on QUETIAPINE FUMARATE at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.